A Californian biotech company has attracted $40 million of investment to develop pioneering cancer treatments.
Vivace Therapeutics raised the sum across two funding rounds and will now prioritise advancing new breakthroughs in the fight against cancer. Based in the San Francisco Bay Area, Vivace Therapeutics draws together world-class scientists, investors and leading business minds from America and China to spearhead a ‘capital-efficient approach to developing novel cancer treatments’.
“Since our founding, we have focused on bringing together the best experts from China and the US to turn novel biology into first-in-class cancer therapeutics,” said Dr Sofie Qiao, president and CEO of Vivace.
The team says it is pulling its diverse talents in a bid to ‘conquer’ cancer.
Dr Tim Shannon, General Partner at Canaan and a founding member of Vivace’s board of directors, added: “With business and scientific leadership in the US, and research capabilities in China, Vivace takes an efficient and innovative approach to drug discovery.”